MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Price-to-Tangible-Book : 4.45 (As of May. 10, 2024)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Price-to-Tangible-Book?

As of today (2024-05-10), MoonLake Immunotherapeutics's share price is $38.515. MoonLake Immunotherapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $8.66. Hence, MoonLake Immunotherapeutics's Price to Tangible Book Ratio of today is 4.45.

The historical rank and industry rank for MoonLake Immunotherapeutics's Price-to-Tangible-Book or its related term are showing as below:

MLTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.64 Med: 7.87 Max: 8.37
Current: 4.7

During the past 3 years, MoonLake Immunotherapeutics's highest Price to Tangible Book Ratio was 8.37. The lowest was 4.64. And the median was 7.87.

MLTX's Price-to-Tangible-Book is ranked worse than
72.85% of 1223 companies
in the Biotechnology industry
Industry Median: 2.75 vs MLTX: 4.70

A closely related ratio is called PB Ratio. As of today, MoonLake Immunotherapeutics's share price is $38.515. MoonLake Immunotherapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $8.66. Hence, MoonLake Immunotherapeutics's P/B Ratio of today is 4.45.

MoonLake Immunotherapeutics Price-to-Tangible-Book Historical Data

The historical data trend for MoonLake Immunotherapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Price-to-Tangible-Book Chart

MoonLake Immunotherapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

8.37

7.37

MoonLake Immunotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial							19.93	5.57	7.18	7.37	-

Competitive Comparison of MoonLake Immunotherapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Price-to-Tangible-Book falls into.

MoonLake Immunotherapeutics Price-to-Tangible-Book Calculation

MoonLake Immunotherapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	38.515	/	8.662
	=	4.45

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

MoonLake Immunotherapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300